NO20052026L - Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet - Google Patents

Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet

Info

Publication number
NO20052026L
NO20052026L NO20052026A NO20052026A NO20052026L NO 20052026 L NO20052026 L NO 20052026L NO 20052026 A NO20052026 A NO 20052026A NO 20052026 A NO20052026 A NO 20052026A NO 20052026 L NO20052026 L NO 20052026L
Authority
NO
Norway
Prior art keywords
verapamil
gastrointestinal motility
treatment
abnormal increases
conditions
Prior art date
Application number
NO20052026A
Other languages
English (en)
Inventor
John G Devane
John Kelly
Original Assignee
Agi Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Ltd filed Critical Agi Therapeutics Ltd
Publication of NO20052026L publication Critical patent/NO20052026L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfirmelsen er rettet mot fremgangsmåter for behandling, forebygging og/eller håndtering av unormale økninger i gastiointestinal bevegelighet og tarmtilstander som forårsaker dette. Slike tilstander inkluderer, men er ikke begrenset til, irritabelt tarmsyndrom (IBS), infeksiøse sykdommer i tyrm- og tykktarmen og symptomer på en hvilken som helst av de foregående tilstandene. Spesielt angår oppfirmelsen fremgangsmåter for anvendelse beriket (R)verapamil så vel som sammensetninger og formuleringer som irmeholder dette.
NO20052026A 2002-09-27 2005-04-26 Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet NO20052026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/256,261 US20030092765A1 (en) 2001-11-15 2002-09-27 Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
PCT/IB2002/005140 WO2004032919A1 (en) 2002-09-27 2002-11-15 Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility

Publications (1)

Publication Number Publication Date
NO20052026L true NO20052026L (no) 2005-04-26

Family

ID=32029241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052026A NO20052026L (no) 2002-09-27 2005-04-26 Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet

Country Status (10)

Country Link
US (2) US20030092765A1 (no)
EP (2) EP1891947A3 (no)
JP (1) JP2006504724A (no)
AU (1) AU2002351118B2 (no)
CA (1) CA2499290A1 (no)
MX (1) MXPA05003177A (no)
NO (1) NO20052026L (no)
NZ (1) NZ539059A (no)
WO (1) WO2004032919A1 (no)
ZA (1) ZA200502306B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060233873A1 (en) * 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8486381B2 (en) * 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
CA2659037A1 (en) * 2006-08-04 2008-03-13 Agi Therapeutics Research Limited Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
US20090023814A1 (en) * 2007-07-18 2009-01-22 Agi Therapeutics Research Ltd. Compositions and methods having mt1 receptor activity
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US20110301245A1 (en) * 2010-06-04 2011-12-08 Agi Therapeutics, Plc (r)-2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril formulaitons, andthe use of such formulations in the treatment of conditions mediated by the serotonin transporter
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
CN108430467B (zh) * 2016-05-20 2021-06-22 晟德大药厂股份有限公司 (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635931A1 (de) * 1986-10-22 1988-04-28 Basf Ag Wirkstoffe zur verhuetung von tumormetastasen
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5910601A (en) 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5892093A (en) 1996-02-08 1999-04-06 Darwin Discovery Limited Resolution
GB9605074D0 (en) 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
AU3205497A (en) * 1996-05-23 1997-12-09 G.D. Searle & Co. Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil
EP0925062A1 (en) * 1996-08-06 1999-06-30 Darwin Discovery Limited Therapeutic utilities of verapamil enantiomers
GB9616504D0 (en) 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use
GB9616549D0 (en) 1996-08-06 1996-09-25 Chiroscience Ltd Therapeutic product and its use

Also Published As

Publication number Publication date
AU2002351118A1 (en) 2004-05-04
JP2006504724A (ja) 2006-02-09
EP1891947A3 (en) 2008-03-05
EP1542673A1 (en) 2005-06-22
WO2004032919A1 (en) 2004-04-22
EP1891947A2 (en) 2008-02-27
AU2002351118B2 (en) 2009-03-12
US20040063784A1 (en) 2004-04-01
MXPA05003177A (es) 2005-11-23
CA2499290A1 (en) 2004-04-22
US20030092765A1 (en) 2003-05-15
US6849661B2 (en) 2005-02-01
ZA200502306B (en) 2006-12-27
NZ539059A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
NO20052026L (no) Anvendelse av (R)-verapamil for behandlingen av unormale okninger i gastrointestinal bevegelighet
NO20073764L (no) Sammensetninger for behandling av HCV
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20061911L (no) Immunogene sammensetninger
NO20052348L (no) Behandling av hemoragisk sjokk
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
EA200700336A1 (ru) Противовирусные соединения
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
NO20044808L (no) Heterosykliske sulfonamider som er hepatitt C virus inhibitorer
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
NO20063449L (no) Substituerte heterocykler og deres anvendelse
SI1567193T1 (sl) Sestavki za čiščenje debelega črevesa
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
EA200702455A1 (ru) Модуляторы индоламин 2,3-диоксигеназы и способы их применения
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
IS7533A (is) Lifrarbólgu C-veirutálmar
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
EA200701297A1 (ru) Соединения пиридазинона
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application